Samil Pharm
Samil Pharmaceutical Co.,Ltd engages in the manufacture and sale of indispensable medicines in South Korea. It offers hepatic, gastrointestinal, vasodilator, antithrombotic, respiratory, skeletal muscle relaxants, circulatory, neurological, antibiotics, metabolic, antihistamines, immunosuppressive, hormone, anti-tumor, urinary, and ophthalmic drugs, as well as antipyretic, analgesic, and anti-inf… Read more
Samil Pharm (000520) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of June 2025: 0.016x
Based on the latest financial reports, Samil Pharm (000520) has a cash flow conversion efficiency ratio of 0.016x as of June 2025.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (₩2.44 Billion) by net assets (₩149.26 Billion). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Samil Pharm - Cash Flow Conversion Efficiency Trend (2012–2024)
This chart illustrates how Samil Pharm's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
Samil Pharm Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Samil Pharm ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
PLINTAS
KLSE:5320
|
N/A |
|
Vaibhav Global Limited
NSE:VAIBHAVGBL
|
0.047x |
|
Donglai Coating Technology (Shanghai) Co. Ltd. A
SHG:688129
|
0.011x |
|
AMTD Digital Inc.
NYSE:HKD
|
0.067x |
|
Guangdong Hotata Technology Group Co Ltd Class A
SHG:603848
|
0.030x |
|
LINE Pay Taiwan Limited
TW:7722
|
-0.057x |
|
Mountain Commerce Bancorp Inc
OTCQX:MCBI
|
N/A |
|
Ceres Power Holdings plc
PINK:CPWHF
|
0.007x |
Annual Cash Flow Conversion Efficiency for Samil Pharm (2012–2024)
The table below shows the annual cash flow conversion efficiency of Samil Pharm from 2012 to 2024.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | ₩176.12 Billion | ₩2.59 Billion | 0.015x | -84.00% |
| 2023-12-31 | ₩127.83 Billion | ₩11.75 Billion | 0.092x | +178.32% |
| 2022-12-31 | ₩125.82 Billion | ₩4.15 Billion | 0.033x | +53.20% |
| 2021-12-31 | ₩65.75 Billion | ₩1.42 Billion | 0.022x | -82.38% |
| 2020-12-31 | ₩63.55 Billion | ₩7.77 Billion | 0.122x | -28.06% |
| 2019-12-31 | ₩62.27 Billion | ₩10.59 Billion | 0.170x | +463.81% |
| 2018-12-31 | ₩56.08 Billion | ₩-2.62 Billion | -0.047x | -163.08% |
| 2017-12-31 | ₩51.17 Billion | ₩3.79 Billion | 0.074x | -30.47% |
| 2016-12-31 | ₩52.87 Billion | ₩5.63 Billion | 0.107x | +98.58% |
| 2015-12-31 | ₩54.41 Billion | ₩2.92 Billion | 0.054x | +124.94% |
| 2014-12-31 | ₩55.42 Billion | ₩-11.92 Billion | -0.215x | -277.61% |
| 2013-12-31 | ₩70.03 Billion | ₩-3.99 Billion | -0.057x | -171.32% |
| 2012-12-31 | ₩62.87 Billion | ₩5.02 Billion | 0.080x | -- |